帕罗西汀合并柴胡逍遥合剂对抑郁症病人生活质量的影响  

Influence of paroxetine combined with Chaihuxiaoyao mixture on life quality of patients with depression

作　　者：张建明[1] 吴海苏[2] 朱丽萍[2] 张六平 汪作为[4] 伍毅[5] 

机构地区：[1]上海交通大学医学院附属上海市精神卫生中心药剂科,上海201108 [2]上海交通大学医学院附属上海市精神卫生中心临床七科,上海201108 [3]上海市黄浦区精神卫生中心精神科,上海200003 [4]上海市虹口区精神卫生中心精神科,上海200083 [5]上海市杨浦区精神卫生中心精神科,上海200090

出　　处：《药学服务与研究》2012年第3期205-208,共4页Pharmaceutical Care and Research

基　　金：上海申康医院发展中心2007年中医验方项目(No.SHDC12007412)

摘　　要：目的:评价柴胡逍遥合剂对抑郁症病人生活质量的影响。方法:190例抑郁症病人随机分为帕罗西汀合并柴胡逍遥合剂组(试验组)及帕罗西汀合并安慰剂组(对照组)。柴胡逍遥合剂和安慰剂剂量均为50ml,bid,帕罗西汀片起始剂量及推荐治疗剂量均为20mg/d,最高剂量为40mg/d。分别于治疗前及治疗8周末进行汉密尔顿抑郁等级量表(HAMD)、36条简明健康状况调查表(SF-36)及治疗紧急症状量表(TESS)评定。结果:完成试验的有效病例为182例,试验组89例,对照组93例。与治疗前比较,两组在治疗8周后,HAMD总分、SF-36各维度分差异均有统计学意义(P<0.01)。治疗8周后,试验组HAMD总分显著低于对照组,SF-36三个维度(精力、情感职能及精神健康)分值高于对照组(P<0.01)。TESS评分及药品不良反应(ADRs)发生率两组无差异(P>0.05),两组均有较高的耐受性,多数ADRs为轻、中度。结论:与单用帕罗西汀相比,帕罗西汀合并柴胡逍遥合剂对抑郁症病人生活质量改善更显著,疗效更明显,ADRs发生率与安慰剂组无显著差异。Objective： To evaluate the influence of Chaihuxiaoyao mixture（CXM） on life quality of patients with depression. Methods： One hundred and ninety patients with depression were randomly divided into paroxetine combined with CXM group （trial group） and paroxetine combined with placebo group （control group）. The doses of CXM and placebo were 50 ml, bid. The initial dose and recommended dose of paroxetine were 20 mg/d, and the highest dose was 40 mg/d. All of the patients had a 8 week treatment. The therapeutic efficacy was evaluated before and after the treatment by Hamilton depression rating scale （HAMD） and the short form-36 health survey （SF-36）, and the adverse drug reactions （ADRs） were evaluated by treat- ment emergent symptom scale （TESS）. Results： One hundred and eighty-two patients completed the trial, 89 cases in trial group and 93 cases in control group. Compared with the baseline, significant differences in HAMD scores and the SF-36 scores were observed in both groups after 8-week treatment （P（0.01）. After 8-week treatment, HAMD scores in trial group were significantly lower than those in control group, and SF-36 scores（vitality,emotional role and mental health） were significantly higher than those in control group（P〈0.01）. There was no statistical difference in ADRs and the TESS scores between two groups（P〉0.05）. Most ADRs were mild and moderate. Conclusion： Paroxetine combined with CXM is more effectiveness and can significantly improve quality of life in patients with depression, and the ADRs rate has no difference compared with placebo control group.

关 键 词：柴胡逍遥合剂 帕罗西汀 抑郁症 生活质量 

分 类 号：R971.43[医药卫生—药品]